Safety And Efficacy In Long Term Use Of Lyrica (Regulatory Post Marketing Commitment Plan)
- Registration Number
- NCT01279850
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Brief Summary
The objective of this investigation is to evaluate the safety and efficacy of long term use with Lyrica in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Lyrica will be monitored during the survey period, and whether an additional treatment outcome investigation and/or a post-marketing clinical study is required in the future will be determined.
- Detailed Description
Patients who fulfill criteria below:
1. Patients who have previously enrolled in A0081261.
2. Patients who have been administered Lyrica for more than 52 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 891
- Patients need to be administered by Lyrica for over 52 weeks in order to be enrolled in the surveillance.
- Patients not administered Lyrica.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Pregabalin (Lyrica) capsule Pregabalin (Lyrica) capsule Patients administered "Pregabalin capsule".
- Primary Outcome Measures
Name Time Method Percentage of Participants With Adverse Drug Reaction From Week 1 to Week 104 at maximum An adverse drug reaction (ADR) was any untoward medical occurrence attributed to LYRICA Capsules in a participant who received LYRICA Capsules. Relatedness to LYRICA Capsules was assessed by the physician.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Serious Adverse Drug Reaction From Week 1 to Week 104 at maximum An adverse drug reaction (ADR) was any untoward medical occurrence attributed to LYRICA Capsules in a participant who received LYRICA Capsules. A serious ADR was an ADR resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Relatedness to LYRICA Capsules was assessed by the physician.
Percentage of Participants With Adverse Drug Reaction Unexpected From Japanese Package Insert From Week 1 to Week 104 at maximum An adverse drug reaction (ADR) was any untoward medical occurrence attributed to LYRICA Capsules in a participant who received LYRICA Capsules. Expectedness of the adverse event was determined according to the Japanese package insert. Relatedness to LYRICA Capsules was assessed by the physician.
Number of Participants With Adverse Drug Reactions Related to Peripheral Edema or Other Edema-related Events From Week 1 to Week 104 at maximum An adverse drug reaction (ADR) was any untoward medical occurrence attributed to LYRICA Capsules in a participant who received LYRICA Capsules. Relatedness to LYRICA Capsules was assessed by the physician. Occurrence of ADRs related to peripheral edema or other edema-related events was evaluated.
Number of Participants With Adverse Drug Reactions Related to Dizziness, Somnolence, Loss of Consciousness, Syncope, and Potential for Accidental Injury From Week 1 to Week 104 at maximum An adverse drug reaction (ADR) was any untoward medical occurrence attributed to LYRICA Capsules in a participant who received LYRICA Capsules. Relatedness to LYRICA Capsules was assessed by the physician. Occurrence of ADRs related to dizziness, somnolence, loss of consciousness, syncope, and potential for accidental injury was evaluated.
Number of Participants With Adverse Drug Reactions Related to Vision-related Events From Week 1 to Week 104 at maximum An adverse drug reaction (ADR) was any untoward medical occurrence attributed to LYRICA Capsules in a participant who received LYRICA Capsules. Relatedness to LYRICA Capsules was assessed by the physician. Occurrence of ADRs related to vision-related events was evaluated.
Physician's Impression (CGIC) at Week 104 At Week 104 The physician's impression (clinical global impression of change \[CGIC\]) at Week 104, as compared to the baseline condition (including the first day of treatment), was rated by the physician on a 7-grade scale.
Change From Baseline in Participant-rated Pain Score at Week 104 Baseline and at Week 104 The pain experienced at Week 104 during the past 24 hours was rated by participants at the time of getting up in the morning on an 11-grade scale, ranging from 0 (no pain) to 10 (the most severe pain possible). Mean change from baseline in participant-rated pain score at Week 104 was presented along with standard deviation.
Clinical Effectiveness Rate At Week 104 Clinical effectiveness of LYRICA Capsules was determined by the physician based on the following categories: (1) effective, (2) ineffective, or (3) impossible to judge at Week 104 of the treatment. Clinical effectiveness rate, which was defined as the percentage of participants who achieved clinical effectiveness over the total number of the analysis population, was presented along with the corresponding 2-sided 95% CI.
Change From Baseline in Participant-rated Sleep Interference Score at Week 104 Baseline and at Week 104 The sleep interference (inability to sleep because of pain) experienced at Week 104 during the past 24 hours was rated by participants at the time of getting up in the morning on an 11-grade scale, ranging from 0 (no disturbance) to 10 (totally unable to sleep because of pain). Mean change from baseline in participant-rated sleep interference score at Week 104 was presented along with standard deviation.
Patient's Impression (PGIC) at Week 104 At Week 104 The patient's impression (patient global impression of change \[PGIC\]) at Week 104, as compared to the baseline condition (including the first day of treatment), was rated by participants on a 7-grade scale.